Inventiva 주식 가격. IVA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

가격

2.785

매수가

2.77

매도가

2.81

거래량

24,609

2.77 일간 변동폭 2.90

1.434 52주 범위 4.30

market_cap

586.718M

전일 종가

2.885

개장가

2.90

최근 거래 시간

2.785

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

34,127

발행 주식

210,670,845

배당수익률

주가수익률

-5.30

주당순이익(EPS)

-0.52

매출

23.16M

순이익

-110.43M

섹터

Biological Pds,ex Diagnstics

산업

Biological Pds,ex Diagnstics

웹사이트

www.inventivapharma.com

본부

Daix, Fra

설립됨

Inventiva is listed in the Biological Pds,ex Diagnstics sector of the 유로넥스트 (Euronext) with ticker IVA. The last closing price for Inventiva was 2.89 €. Over the last year, Inventiva shares have traded in a share price range of 1.434 € to 4.30 €.

Inventiva currently has 210,670,845 shares in issue. The market capitalisation of Inventiva is 607.79 € million. Inventiva has a price to earnings ratio (PE ratio) of -5.30.

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de...

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal...

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and...

Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1

Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du...

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the...

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first...

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et MASLD

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un...

기간	변동	변동 %	시가	고가	저가	평균 일일 거래량	VWAP
1	-0.005	-0.179211469534	2.79	2.9	2.545	41157	2.69642366	DE
4	0.52	22.9580573951	2.265	3.2	2.2	54102	2.72948533	DE
12	0.585	26.5909090909	2.2	3.2	2	34127	2.53350529	DE
26	0.685	32.619047619	2.1	3.2	1.434	44157	2.38422227	DE
52	-0.615	-18.0882352941	3.4	4.3	1.434	43264	2.70638649	DE
156	-7.215	-72.15	10	10.48	1.434	55569	3.5905361	DE
260	-0.515	-15.6060606061	3.3	16.16	1.434	63640	7.06896751	DE

IVA - Frequently Asked Questions (FAQ)

What is the current Inventiva share price?

The current share price of Inventiva is 2.785 €

How many Inventiva shares are in issue?

Inventiva has 210,670,845 shares in issue

What is the market cap of Inventiva?

The market capitalisation of Inventiva is EUR 607.79M

What is the 1 year trading range for Inventiva share price?

Inventiva has traded in the range of 1.434 € to 4.30 € during the past year

What is the PE ratio of Inventiva?

The price to earnings ratio of Inventiva is -5.3

What is the cash to sales ratio of Inventiva?

The cash to sales ratio of Inventiva is 25.3

What is the reporting currency for Inventiva?

Inventiva reports financial results in EUR

What is the latest annual turnover for Inventiva?

The latest annual turnover of Inventiva is EUR 23.16M

What is the latest annual profit for Inventiva?

The latest annual profit of Inventiva is EUR -110.43M

What is the registered address of Inventiva?

The registered address for Inventiva is 50 RUE DE DIJON, DAIX, 21121

What is the Inventiva website address?

The website address for Inventiva is www.inventivapharma.com

Which industry sector does Inventiva operate in?

Inventiva operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

가장 활성
% 상승자
% 패자

기호	가격	볼륨
DMSBSDiagnostic Medical Systems	0.0175 € (775.00%)	100k
ALBOOBOOSTHEAT	0.0066 € (43.48%)	919.17k
MLGEQGentlemen S Equity SA	0.018 € (38.46%)	1,000
MLCOTCoretech 5	0.051 € (34.21%)	300
ALCBXCibox Interactive	0.0316 € (32.77%)	3.69M
MLAZRThe Azur Selection SA	0.76 € (-32.14%)	24.83k
ALVERVergnet	0.0003 € (-25.00%)	365.71M
ALHPIHopium SA	0.002 € (-20.00%)	18.72M
ALDOLDolfines	2.60 € (-18.75%)	58.45k
MLPHOPhotonike Capital	0.104 € (-18.11%)	8.24k
ATOAtos SE	0.0037 € (-13.95%)	2.95B
ALVERVergnet	0.0003 € (-25.00%)	365.71M
ALCYBCybergun	0.0002 € (0.00%)	187.24M
ALTDTonner Drones	0.021 € (-13.93%)	103.36M
ALEUPEuroplasma	0.0218 € (-13.49%)	99.9M

NYBob 4 분 전

BREAKING! UKRAINE AGREES TO CEASEFIRE WITH RUSSIA...
BUT THERE'S A BIG CATCH | Redacted News
Redacted News
580K followers

https://1a-1791.com/video/fwe1/62/s8/1/m/g/S/r/mgSry.oq1b.5-small-BREAKING-UKRAINE-AGREES-TO-.jpg

https://rumble.com/v6qhn64-

lj: Given that Canada is starting to cry "uncle", I think tomorrow will be an "up" day in the market.

RichieBoy 6 분 전

Can't eat and post at same time. Hell chewing gum is a challenge when you only have one pinkie left. Chicken and Chips is serious comfort food alright.

https://www.linkedin.com/company/livohealth/

AFFU

axelvento 7 분 전

Analysts at Evercore ISI said today’s readout would be “likely sufficient for approval in ESR1m patients, but not dramatic.”

let's see what happens------

PFE

NYBob 7 분 전

STAR NEWS - BREAKING! UKRAINE AGREES TO CEASEFIRE WITH RUSSIA...
BUT THERE'S A BIG CATCH | Redacted News
Redacted News
580K followers

https://1a-1791.com/video/fwe1/62/s8/1/m/g/S/r/mgSry.oq1b.5-small-BREAKING-UKRAINE-AGREES-TO-.jpg

https://rumble.

EBS NCI

ORCA 7 분 전

ITS OVER.FOR AXXA.FOR SURE.IMO.IT IS HEADING TO ZERO BID.BORIS PARTY OVER.THE SUCKERS RUN OUT OF MONEY.YOU EVEN GOT ME LOSING MONEY THIS TIME AROUND DIRTY BAG.BUT ORCA LOSING MONEY IT MEANS THE END BORIS.THE END.

AXXA

NYBob 8 분 전

EBS NCI

bbotcs 9 분 전

lj: Still holding KOLD. I plan to sell on Friday.

KOLD

axelvento 11 분 전

I saw-----

The magnitude of PFS improvement in patients with the ESR1 mutation with vepdegestrant “exceeded the pre-specified target” of a 40% reduction in the risk of death or disease progression, according to the release, though Pfizer and Arvinas did not provide a more specific fig

PFE

bbotcs 11 분 전

lj: In Republican Red! Being from New York City, I wonder whether Trump has even driven in his 78 years!

ORCA 12 분 전

SS HAS BEEN CHANGED AGAIN.THE RESTRICTED IS NOW 1,398,5 BILLION.FROM 1,435 BILLION.37 MILLION HAVE BEEN ADDED TO THE FLOAT.
Outstanding Shares
3,653,305,519
03/04/2025
Restricted
1,398,453,634
03/04/2025
Unrestricted
2,254,851,885
03/04/

VPLM

BDEZ 12 분 전

Self driving & service KFC food truck in China

Imagine what would happen if you release this thing in any large Western city.

We can’t have nice things anymore.

https://x.com/iamyesyouareno/status/1899424343030972667

nagoya1 13 분 전

Too funny, coming from the internal dialogue gse flip flopping poster. Fnma

FNMA

dinogreeves 14 분 전

I grew a set a long time ago on the streets in my formative years. I don't drink wine, gives me a headache, I like cheese though. I am not whining, I am shorting the SPY and love every minute of it. What better way to hedge. It seems you are on the same boat?

SMCI

Zorax 15 분 전

miss crushie, you probably believe shittypants lie that the us gave Ukraine more than 300 billion since the beginning.
It was less than 100 billion and most of that was not cash to Ukraine, but money from your taxes paid our own overpriced defense contractors.

EU are the ones t

axelvento 15 분 전

Moderna at Barclays Conference: Strategic Focus on Oncology and Vaccines

On Tuesday, 11 March 2025, Moderna Inc. (NASDAQ: MRNA) presented at the Barclays 27th Annual Global Healthcare Conference

https://www.investing.com/news/transcripts/moderna-at-barclays-conference-s

MRNA

nagoya1 15 분 전

Do you have a gse link.
Otherwise just a bubble gum wrapper.
Fnma

FNMA

KOmani 16 분 전

If this can get some traction and break $0.03 and build towards $0.05 tomorrow, I will be more willing fo believe.

I may even buy a few if that happens.

I can see things coming together ... I just don't want to be the only one seeing ....

NEWH

littlejohn 17 분 전

yep, put prices looking groovy again...

they elevated call option prices Wednesday

without a firm uptrend to add more to

the premium, always a sign of caution...

hopefully wrong about that this time...

so we watch...LJ

SMCI

ORCA 18 분 전

ITS TIME TO SEE .006s.THERE WILL BE NO NEWS FOR MANY WEEKS.THUS IT IS TIME TO SEE .006 AND POSSIBLY .005.LONGS ARE BROKE.THE SHORT TERM HAS BEEN A DISASTER.FROM .0188 TO .0075.UNREAL.I CHANGE MY TRADING STYLE.FOR VPLM.FROM CARS,I DOWN GRADE IT TO CHICKEN TRIO PROFITS AGAIN.THE SS CHANGED AGAIN.INSI

VPLM

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Inventiva (IVA)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Inventiva 정보

IVA 최신 뉴스

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et MASLD

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité

IVA - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

Inventiva (IVA) 시세

Inventiva (IVA)

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

주요 통계 및 세부정보

Inventiva 정보

IVA 최신 뉴스

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva annonce la publication dans la revue « Journal of Hepatology » des résultats de l’étude clinique de preuve de concept initiée par un investigateur évaluant lanifibranor chez des patients atteints de DT2 et MASLD

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

Inventiva annonce la publication dans Biomedicine & Pharmacotherapy des résultats d'une étude préclinique montrant une amélioration de l'hypertension portale avec le traitement par lanifibranor

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial

Inventiva et Hepalys Pharma, Inc. annoncent le lancement du programme de développement clinique de lanifibranor au Japon avec l'inclusion du premier participant dans l'étude de Phase 1

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update

Inventiva publie ses résultats financiers préliminaires pour l'exercice fiscal 2024¹ et fait le point sur son activité

IVA - Frequently Asked Questions (FAQ)

이동자

토론

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거